Sage Group (SGPYY)

PNK: SGPYY · Real-Time Price · USD

66.00

-0.05 (-0.08%)

At close: May 01, 2025, 3:58 PM

-0.08% (1D)

Bid	65.9
Market Cap	16.06B
Revenue (ttm)	2.25B
Net Income (ttm)	267M
EPS (ttm)	1.68
PE Ratio (ttm)	39.29
Forward PE	n/a
Analyst	n/a

Ask	66.13
Volume	159
Avg. Volume (20D)	33,732
Open	66.02
Previous Close	66.05
Day's Range	65.81 - 66.17
52-Week Range	49.22 - 68.45
Beta	0.42

About SGPYY

The Sage Group plc, together with its subsidiaries, provides technology solutions and services for small and medium businesses in North America, Northern Europe, and internationally. It offers cloud native solutions, such as Sage Intacct, a cloud accounting software products and financial management solutions; Sage People, a cloud HR and people management solution; Sage Accounting, a solution for small businesses, accountants, and bookkeepers to ...

[Read more]

Industry Software - Application

Sector Technology

IPO Date Oct 4, 2007

Employees 10,740

Stock Exchange PNK

Ticker Symbol SGPYY

Website https://www.sage.com

Full Company Profile

News

1 day ago · zacks.com

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

2 days ago · businesswire.com

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong gro...

1 week ago · newsfilecorp.com

Sage Potash Appoints Tim Mizuno as President and Chief Operating Officer and Announces Loan Agreement

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce the appointment of Tim Mizuno as ...

3 weeks ago · seekingalpha.com

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals...

1 month ago · reuters.com

UK's Sage Group says Cartin to replace Howell as CFO next year

British software firm Sage Group named Jacqui Cartin as its new chief financial officer on Thursday, succeeding Jonathan Howell, who will leave on December 31.

1 month ago · newsfilecorp.com

Greenbriar Completes Major Water Acquisition for Sage Ranch

Scottsdale, Arizona--(Newsfile Corp. - March 17, 2025) - Greenbriar Sustainable Living Inc. (TSXV: GRB) (OTC Pink: GEBRF) ("Greenbriar" or the "Company") is pleased to announce that it has reached a b...

1 month ago · businesswire.com

Sage Therapeutics Announces R&D Leadership Transition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Compa...

2 months ago · zacks.com

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

2 months ago · businesswire.com

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. “We ar...